Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics reported a board committee leadership change following the resignation of Dr. Kunkel. The board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., who is already a board member and a member of the Clinical and Commercialization Committee, to serve as chair of that committee effective September 1, 2025. The change is administrative and focused on committee leadership; no financial data, transactions, or other operational actions are disclosed in the filing.